Isolated lung transplantation for end-stage lung disease: a viable therapy.
Since January 1990, we have performed 29 isolated lung transplantations in 28 patients with end-stage lung disease (12 single, 16 bilateral). Recipient diagnoses were: cystic fibrosis (11), chronic obstructive pulmonary disease (6), pulmonary fibrosis (6), eosinophilic granulomatosis (1), postinfectious lung disease (1), adult respiratory distress syndrome (1), and primary pulmonary hypertension (2). There have been four deaths, two in patients with pulmonary fibrosis and two in patients with primary pulmonary hypertension. Four patients have undergone transplantation while on ventilatory support for respiratory failure (2 with cystic fibrosis, 1 having redo lung transplantation with cystic fibrosis, and 1 with adult respiratory distress syndrome); all of these have survived. Six patients required cardiopulmonary bypass, which was associated with increased transfusion requirement. All patients 2 months after discharge have returned to an active life-style, except for 2 patients who currently await retransplantation. Preoperative pulmonary rehabilitation has resulted in significant improvement in exercise performance in all patients. Immunosuppression consists of cyclosporine, azathioprine, and antilymphoblast globulin (University of Minnesota), withholding systemic steroids in the early postoperative period. We have employed bronchial omentopexy in all but four transplants; there has been one partial bronchial dehiscence, two instances of bronchomalacia requiring internal stenting, and one airway stenosis. Cytomegalovirus disease has been seen frequently (15 cases), but has responded well to treatment with ganciclovir. Other complication shave included one drug-related prolonged postoperative ventilation, thrombosis of a left lung after bilateral lung transplantation requiring retransplantation, five episodes of unilateral phrenic nerve palsy after bilateral lung transplantation (4 resolved), and the requirement of massive transfusion (greater than 10 units) in 5 patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Egan
T M
TM
Division of Cardiothoracic Surgery, University of North Carolina School of Medicine, Chapel Hill.
Westerman
J H
JH
Lambert
C J
CJ
Detterbeck
F C
FC
Thompson
J T
JT
Mill
M R
MR
Keagy
B A
BA
Paradowski
L J
LJ
Wilcox
B R
BR
D000293:Adolescent; D000328:Adult; D001424:Bacterial Infections / Q000209:etiology; D003550:Cystic Fibrosis / Q000503:physiopathology / Q000601:surgery; D005260:Female; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D007165:Immunosuppression Therapy; D008168:Lung / Q000503:physiopathology / Q000601:surgery; D008171:Lung Diseases / Q000503:physiopathology / Q000601:surgery*; D008173:Lung Diseases, Obstructive / Q000503:physiopathology / Q000601:surgery; D016040:Lung Transplantation / Q000009:adverse effects / Q000379:methods* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D015996:Survival Rate; D014797:Vital Capacity / Q000502:physiology